CD19 and B-cell chronic lymphocytic leukemia: In the future, combination with new drugs such as ibrutinib, venetoclax, and idelalisib, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.